During capital-constrained periods, founders must be ruthless in their focus. Every dollar and hour should go towards "killer experiments"—those that directly accrue value and hit the specific milestones required for the next fundraising round. "Cool science" that doesn't advance these goals is a luxury companies can't afford.

While Novogaia is building a next-gen discovery platform, CEO Tess Bevers emphasizes that the company's primary focus must be advancing its first drug candidates. For early-stage biotechs, the tangible value lies in getting molecules further down the pipeline, not just in perfecting the underlying technology.

During market downturns, biotech companies lose the ability to raise capital simply when it's convenient. Financing becomes tied to specific events. The key is timing a fundraise immediately before or after the release of significant clinical data that de-risks the company and attracts new investors.

The recent biotech market downturn raised the bar for going public. Unlike the 2020-2021 period where preclinical companies IPO'd, today's successful offerings are from companies with mid-to-late-stage clinical programs. This de-risked profile is necessary to attract both specialist and crucial generalist investors back to the sector.

K-36's lead drug was acquired from Novartis not because it was a failed asset, but because it became available during a strategic reorganization. This illustrates a key opportunity for biotech startups: licensing promising preclinical assets that no longer fit a large pharmaceutical company's immediate development focus.

While a challenging fundraising market seems negative, it forces startups to operate with discipline. Unlike in frothy markets where companies expand based on hype, the current climate rewards tangible results. This compels a lean structure focused on high-value projects, creating a healthier long-term business model.

In a tough funding market, a strong mission isn't enough. Kenai succeeded by combining its patient-focused narrative with compelling preclinical data demonstrating the superior potency and dopamine production of its cell therapy candidate, which engaged and convinced investors.

During capital-constrained periods, investors fixate on the single biggest value driver, usually a lead clinical asset. While platforms have value, companies must focus on the asset with the most compelling data to secure funding.

The tough funding environment forced Stellular Bio into "extreme focus" on a single asset. This meant deferring all non-essential R&D, like manufacturing scale-up, to create the most capital-efficient, linear path to an IND filing and first clinical data—the next major value inflection point for investors.